Atopic Dermatitis News
- Alert Anzupgo Approved in Europe for Severe Hand Eczema
- Delgocitinib Effective for Hand Eczema in Phase 3 Studies
- Cendakimab Clears Skin in Adults With Atopic Dermatitis
- AD in Older Adults: Common, Unique, Challenging to Manage
- Alert FDA Approves Topical Eczema Rx for Ages 6 or Older
- Dupilumab Safe, Effective Over 5 Years in Moderate-Severe AD
- Review: Dupilumab Benefits Kids With AD and Alopecia Areata
- Dupilumab Effective in PPI-Refractory Pediatric EoE
- Upadacitinib User Survey Confirms Eczema Clinical Data
- US Eczema Prevalence Highest in Children and Adult Women
- What's the MACE Risk With Moderate to Severe Eczema?
- Can Dupilumab Halt Atopic March in Pediatric AD?
- Topical Treatment Effective for Young Kids Up to 52 Weeks
- Lower Eczema Risk: Another Reason to Reduce Sodium Intake?
- Alert FDA Extends Upadacitinib Indications to Kids With Arthritis
- Antibiotics in Pregnancy Linked to Dermatitis in Babies
- EMA Backs Approving Sanofi's Dupixent for 'smoker's Lungs', FDA Extends Review
- Dupilumab: Future Treatment for Pediatric Alopecia Areata?
- Tapinarof Cream Effective For AD, Down to Age 2 Years
- Parental e-Cigarette Use May Increase AD Risk in Children